Immune Checkpoint Inhibitor Use, Multimorbidity and Healthcare Expenditures Among Older Adults with Late-stage Melanoma

Overview

Journal Immunotherapy

Specialties Allergy & Immunology
Pharmacology

Date 2020 Nov 5

PMID 33148082

Citations 2

Authors

Pragya Rai

Chan Shen

Joanna Kolodney

Kimberly M Kelly

Virginia G Scott

Usha Sambamoorthi

Affiliations

Soon will be listed here.

Abstract

The objective of this study is to assess the impact of immune checkpoint inhibitors (ICIs) and multimorbidity on healthcare expenditures among older patients with late-stage melanoma. A retrospective longitudinal cohort study using Surveillance, Epidemiology and End Results linked with Medicare claims was conducted. Generalized linear mixed models were used to analyze adjusted relationships of ICI, multimorbidity and ICI-multimorbidity interaction on average healthcare expenditures. Patients who received ICI and those who had multimorbidity had significantly higher average total healthcare expenditures compared with ICI nonusers and no multimorbidity. In the fully adjusted model using ICI-multimorbidity interaction, no excess cost was added by multimorbidity. Use of ICIs, regardless of multimorbidity, is associated with increased healthcare expenditures.

Citing Articles

Marginal health care expenditures for melanoma care in the United States.

Olateju O, Li J, Thornton J, Aparasu R J Manag Care Spec Pharm. 2024; 30(12):1364-1374.

PMID: 39612258 PMC: 11607212. DOI: 10.18553/jmcp.2024.30.12.1364.

The Affordable Care Act and income-based disparities in health care coverage and spending among nonelderly adults with cancer.

Olateju O, Shen C, Thornton J Health Aff Sch. 2024; 2(5):qxae050.

PMID: 38812986 PMC: 11135644. DOI: 10.1093/haschl/qxae050.

References

Ghate S, Ionescu-Ittu R, Burne R, Ndife B, Laliberte F, Nakasato A . Healthcare resource utilization in patients with metastatic melanoma receiving first-line therapy with dabrafenib + trametinib versus nivolumab or pembrolizumab monotherapy. Curr Med Res Opin. 2018; 34(12):2169-2176. DOI: 10.1080/03007995.2018.1501351. View

King D, Xiang J, Pilkerton C . Multimorbidity Trends in United States Adults, 1988-2014. J Am Board Fam Med. 2018; 31(4):503-513. PMC: 6368177. DOI: 10.3122/jabfm.2018.04.180008. View

Fitzmaurice C, Dicker D, Pain A, Hamavid H, Moradi-Lakeh M, MacIntyre M . The Global Burden of Cancer 2013. JAMA Oncol. 2015; 1(4):505-27. PMC: 4500822. DOI: 10.1001/jamaoncol.2015.0735. View

Tangka F, Trogdon J, Richardson L, Howard D, Sabatino S, Finkelstein E . Cancer treatment cost in the United States: has the burden shifted over time?. Cancer. 2010; 116(14):3477-84. DOI: 10.1002/cncr.25150. View

Narang A, Nicholas L . Out-of-Pocket Spending and Financial Burden Among Medicare Beneficiaries With Cancer. JAMA Oncol. 2016; 3(6):757-765. PMC: 5441971. DOI: 10.1001/jamaoncol.2016.4865. View

Lohr K . Medicare: a strategy for quality assurance. J Qual Assur. 1990; 13(1):10-3. DOI: 10.1111/j.1945-1474.1991.tb00115.x. View

Coughlin S, Caplan L, Young L . A review of cancer outcomes among persons dually enrolled in Medicare and Medicaid. J Hosp Manag Health Policy. 2018; 2. PMC: 6085746. View

Karimkhani C, Green A, Nijsten T, Weinstock M, Dellavalle R, Naghavi M . The global burden of melanoma: results from the Global Burden of Disease Study 2015. Br J Dermatol. 2017; 177(1):134-140. PMC: 5575560. DOI: 10.1111/bjd.15510. View

Verma V, Haque W, Cushman T, Lin C, Simone 2nd C, Chang J . Racial and Insurance-related Disparities in Delivery of Immunotherapy-type Compounds in the United States. J Immunother. 2019; 42(2):55-64. DOI: 10.1097/CJI.0000000000000253. View

10.

Larkin J, Chiarion-Sileni V, Gonzalez R, Grob J, Cowey C, Lao C . Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med. 2015; 373(1):23-34. PMC: 5698905. DOI: 10.1056/NEJMoa1504030. View

11.

Jain V, Venigalla S, K Reddy V, Lukens J, Mitchell T, Shabason J . Association of Insurance Status With Presentation, Treatment, and Survival in Melanoma in the Era of Immune Checkpoint Inhibitors. J Immunother. 2019; 43(1):8-15. DOI: 10.1097/CJI.0000000000000294. View

12.

Robert C, Schachter J, Long G, Arance A, Grob J, Mortier L . Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med. 2015; 372(26):2521-32. DOI: 10.1056/NEJMoa1503093. View

13.

Toy E, Vekeman F, Lewis M, Oglesby A, Duh M . Costs, resource utilization, and treatment patterns for patients with metastatic melanoma in a commercially insured setting. Curr Med Res Opin. 2015; 31(8):1561-72. DOI: 10.1185/03007995.2015.1062356. View

14.

Lochner K, Cox C . Prevalence of multiple chronic conditions among Medicare beneficiaries, United States, 2010. Prev Chronic Dis. 2013; 10:E61. PMC: 3652723. DOI: 10.5888/pcd10.120137. View

15.

Andrews A . Treating with Checkpoint Inhibitors-Figure $1 Million per Patient. Am Health Drug Benefits. 2015; 8(Spec Issue):9. PMC: 4570079. View

16.

Hegde U, Grant-Kels J . Metastatic melanoma in the older patient: special considerations. Clin Dermatol. 2013; 31(3):311-6. DOI: 10.1016/j.clindermatol.2012.08.011. View

17.

Schneider K, ODonnell B, Dean D . Prevalence of multiple chronic conditions in the United States' Medicare population. Health Qual Life Outcomes. 2009; 7:82. PMC: 2748070. DOI: 10.1186/1477-7525-7-82. View

18.

Yabroff K, Lund J, Kepka D, Mariotto A . Economic burden of cancer in the United States: estimates, projections, and future research. Cancer Epidemiol Biomarkers Prev. 2011; 20(10):2006-14. PMC: 3191884. DOI: 10.1158/1055-9965.EPI-11-0650. View

19.

de Oliveira C, Pataky R, Bremner K, Rangrej J, Chan K, Cheung W . Estimating the Cost of Cancer Care in British Columbia and Ontario: A Canadian Inter-Provincial Comparison. Healthc Policy. 2017; 12(3):95-108. PMC: 5344366. View

20.

Picco L, Achilla E, Abdin E, Chong S, Vaingankar J, McCrone P . Economic burden of multimorbidity among older adults: impact on healthcare and societal costs. BMC Health Serv Res. 2016; 16:173. PMC: 4862090. DOI: 10.1186/s12913-016-1421-7. View